An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT

BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll). MET...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Curr Oncol
Glavni autori: Kouroukis, C.T., Crump, M., MacDonald, D., Larouche, J.F., Stewart, D.A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S.G., Christofides, A., Di Clemente, S., Sehn, L.
Format: Artigo
Jezik:Inglês
Izdano: Multimed Inc. 2015
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530811/
https://ncbi.nlm.nih.gov/pubmed/26300664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2431
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items